ERBB2 and breast cancer: Furthermore, small-molecule tyrosine kinase inhibitors (TKIs), such as neratinib andtucatinib, have demonstrated efficacy in overcoming resistance to trastuzumab andimproving outcomes for patients with HER2-positive BC [13][14].